MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:53:00Z
7 Billion-Dollar Stocks That Deserve a Spot in Your Portfolio
Mon 15 Jul 24, 12:00 AM3 Stocks for Patient Investors Looking to Build Generational Wealth
Sun 14 Jul 24, 12:00 AMPharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
Fri 12 Jul 24, 02:10 PMEli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
Tue 09 Jul 24, 02:17 PMHot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Tue 09 Jul 24, 12:00 AMEli Lilly Snaps Up Morphic For $3.2 Billion; Morphic Stock Hits The Stratosphere
Mon 08 Jul 24, 08:14 PMEli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Nearly Doubles.
Mon 08 Jul 24, 11:51 AMEli Lilly to Buy Morphic Holding for $3.2 Billion
Mon 08 Jul 24, 11:16 AMLilly agrees to buy US biotech Morphic in $3.2 billion deal
Mon 08 Jul 24, 11:06 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -58.97400M | -95.54200M | -45.56900M | -42.41600M | -23.83100M |
| Minority interest | - | - | - | - | - |
| Net income | -59.04100M | -94.24000M | -44.99900M | -43.32800M | -23.83100M |
| Selling general administrative | 32.14M | 27.81M | 18.50M | 10.23M | 5.36M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 70.81M | 19.79M | 44.95M | 16.98M | 3.36M |
| Reconciled depreciation | 1.00M | 1.03M | 1.13M | 0.82M | 0.54M |
| Ebit | -64.40100M | -96.83600M | -48.30600M | -46.98800M | -24.62800M |
| Ebitda | -63.39600M | -95.80600M | -47.18000M | -46.16700M | -24.08900M |
| Depreciation and amortization | 1.00M | 1.03M | 1.13M | 0.82M | 0.54M |
| Non operating income net other | - | - | 1.61M | - | - |
| Operating income | -63.39600M | -95.80600M | -47.18000M | -46.98800M | -24.62800M |
| Other operating expenses | 134.20M | 115.60M | 92.12M | 63.97M | 27.99M |
| Interest expense | 4.57M | 0.27M | 2.74M | 4.57M | 0.00000M |
| Tax provision | 0.07M | 0.00000M | -0.57000M | 0.91M | 0.00000M |
| Interest income | 4.57M | 0.27M | 1.63M | 4.67M | 0.87M |
| Net interest income | 4.57M | 0.27M | 1.63M | 4.67M | 0.87M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.07M | -1.30200M | -0.57000M | 0.91M | 0.80M |
| Total revenue | 70.81M | 19.79M | 44.95M | 16.98M | 3.36M |
| Total operating expenses | 134.20M | 115.60M | 92.12M | 63.97M | 27.99M |
| Cost of revenue | - | - | - | 53.73M | 22.63M |
| Total other income expense net | 4.42M | 0.26M | 1.61M | 4.57M | -0.07400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -59.04100M | -95.54200M | -44.99900M | -43.32800M | -23.83100M |
| Net income applicable to common shares | -59.04100M | -95.54200M | -44.99900M | -43.32800M | -23.83100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 722.51M | 368.59M | 426.29M | 242.38M | 247.44M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 12.58M | 13.93M | 10.20M | 11.17M | 3.09M |
| Total liab | 25.49M | 19.47M | 89.59M | 97.19M | 106.52M |
| Total stockholder equity | 697.02M | 349.12M | 336.70M | 145.20M | 140.92M |
| Deferred long term liab | - | - | - | 57.75M | - |
| Other current liab | 17.08M | 11.69M | 11.63M | 39.44M | 6.73M |
| Common stock | 0.00500M | 0.00400M | 0.00400M | 0.00300M | 0.00300M |
| Capital stock | 0.00500M | 0.00400M | 0.00400M | 0.00300M | 0.00300M |
| Retained earnings | -449.19000M | -297.09500M | -238.05400M | -142.51200M | -97.51300M |
| Other liab | - | - | 51.33M | 57.75M | 71.17M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.77M | 7.96M | 0.34M | 0.42M |
| Cash | 58.58M | 59.27M | 408.13M | 228.26M | 101.56M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 24.78M | 17.13M | 38.26M | 39.44M | 35.35M |
| Current deferred revenue | -1.62800M | 0.47M | 20.63M | 25.27M | 23.45M |
| Net debt | -56.23300M | -55.43400M | -403.08600M | -228.26400M | -101.55900M |
| Short term debt | 1.63M | 1.49M | 1.21M | -29.11100M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 2.34M | 3.84M | 5.05M | - | - |
| Other stockholder equity | 1143.92M | 649.55M | 575.23M | 287.73M | -9.05100M |
| Property plant equipment | - | 5.63M | 7.39M | 2.61M | 3.45M |
| Total current assets | 716.93M | 362.18M | 418.33M | 239.44M | 243.57M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 349.12M | 336.70M | 145.20M | 140.92M |
| Short term investments | 645.77M | 288.98M | 236.70M | 126.22M | 135.46M |
| Net receivables | 0.00000M | 0.46M | 2.31M | 7.31M | 3.47M |
| Long term debt | - | - | - | - | - |
| Inventory | - | -0.45500M | -2.30700M | -7.31400M | - |
| Accounts payable | 7.70M | 3.48M | 4.80M | 3.85M | 5.17M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.29M | -3.33900M | -0.48200M | -0.02100M | 0.04M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00300M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -142.51200M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.13M | 0.77M | 0.57M | 0.34M | 0.42M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5.59M | 6.41M | 7.96M | 2.95M | 3.86M |
| Capital lease obligations | 2.34M | 3.84M | 5.05M | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -56.45100M | -112.16000M | 8.72M | -135.98600M | -0.65600M |
| Change to liabilities | -69.20000M | -13.85100M | -9.01600M | 0.93M | 97.50M |
| Total cashflows from investing activities | -56.45100M | -113.18000M | 8.18M | -135.98600M | -0.65600M |
| Net borrowings | - | - | - | - | -0.65200M |
| Total cash from financing activities | 45.27M | 266.31M | 38.30M | 93.30M | 89.47M |
| Change to operating activities | -5.59500M | -2.50800M | 2.76M | 1.35M | 1.05M |
| Net income | -59.04100M | -95.54200M | -44.99900M | -43.32800M | -23.83100M |
| Change in cash | -112.16200M | 69.67M | 0.49M | -84.34200M | 165.15M |
| Begin period cash flow | 171.99M | 102.32M | 101.83M | 186.18M | 21.02M |
| End period cash flow | 59.83M | 171.99M | 102.32M | 101.83M | 186.18M |
| Total cash from operating activities | -100.97700M | -83.46100M | -45.99000M | -41.65100M | 76.34M |
| Issuance of capital stock | 39.21M | 265.22M | 33.65M | 93.27M | 90.12M |
| Depreciation | 1.00M | 1.03M | 1.13M | 0.82M | 0.54M |
| Other cashflows from investing activities | - | - | - | -133.82800M | 0.00300M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -2.50800M | 2.83M | 1.41M | - |
| Change to account receivables | 1.85M | 5.01M | -3.84700M | -3.46700M | -3.46700M |
| Sale purchase of stock | 0.89M | 1.09M | 1.11M | 93.30M | 90.12M |
| Other cashflows from financing activities | 5.17M | -113.18000M | 3.53M | 0.03M | 90.12M |
| Change to netincome | 30.00M | 22.40M | 11.05M | 2.04M | 1.07M |
| Capital expenditures | 0.36M | 1.02M | 0.54M | 2.16M | 0.66M |
| Change receivables | - | - | -3.84700M | - | - |
| Cash flows other operating | - | - | -0.75700M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 0.49M | - | - |
| Change in working capital | -72.94300M | -11.35200M | -13.62000M | -1.18700M | 98.56M |
| Stock based compensation | 29.05M | 21.18M | 11.05M | 3.53M | 1.00M |
| Other non cash items | 0.95M | 1.22M | 0.45M | -0.02200M | 0.04M |
| Free cash flow | -101.34200M | -84.48100M | -46.53400M | -43.80900M | 75.68M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MORF Morphic Holding Inc |
- -% | 56.55 | - | - | 2752.53 | 2.06 | 1405.11 | -4.1221 |
| NVO Novo Nordisk A/S |
-2.29 1.74% | 129.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.80 2.90% | 135.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.67 0.75% | 494.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
22.92 2.16% | 1083.78 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
35 Gatehouse Drive, A2, Waltham, MA, United States, 02451
| Name | Title | Year Born |
|---|---|---|
| Dr. Praveen P. Tipirneni M.D. | CEO, MD & Director | 1968 |
| Dr. Bruce N. Rogers Ph.D. | Pres | 1969 |
| Dr. Timothy A. Springer Ph.D. | Founder, Independent Director & Member of Scientific Advisory Board | 1948 |
| Dr. Marc Schegerin M.B.A., M.D. | CFO & COO | 1976 |
| Mr. William D. DeVaul Esq. | Gen. Counsel & Sec. | 1971 |
| Mr. Robert E. Farrell Jr., CPA, CPA | Sr. VP of Fin. & Operations and Chief Accounting Officer | 1965 |
| Dr. Blaise Lippa Ph.D. | Chief Scientific Officer | NA |
| Mr. Aaron Pelta | Sr. VP of Bus. & Corp. Devel. | NA |
| Ms. Joanne Gibbons | Sr. VP of Regulatory Affairs | NA |
| Dr. Bruce N. Rogers Ph.D. | President & Interim Principal Executive Officer | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...